

Supplemental Online Content


Schmoll H-J, Lindner LH, Reichardt P, et al. Efficacy of pazopanib with or without gemcitabine in patients with anthracycline- and/or ifosfamide-refractory soft tissue sarcoma: final results of the PAPAGEMO phase 2 randomized clinical trial. *JAMA Oncol*. Published online December 23, 2020. doi:10.1001/jamaoncol.2020.6564

eFigure 1. Exploratory subgroup analyses for Overall survival in patients receiving subsequent gemcitabine or not (A), progression free survival (PFS) in liposarcoma patients (B), according to the use of prior gemcitabine (C) or not (D) and effect of concomitant use of proton pump inhibitors (PPI) in arm A (E) and B (F)

eFigure 2. Forest plot exploratory subgroup analyses for progression free survival (PFS) and overall survival (OS)


This supplemental material has been provided by the authors to give readers additional information about their work.

eFigure 1 Exploratory subgroup analyses for Overall survival in patients receiving subsequent gemcitabine or not (A), Progression free survival (PFS) in liposarcoma patients (B), according to the use of prior gemcitabine (C) or not (D) and effect of concomitant use of proton pump inhibitors (PPI) in arm A (E) and B (F)



Kaplan-Meier estimate with pointwise 95% CI; Abbreviations N number of patients, mOS median Overall Survival, mPFS – median progression free survival, na not applicable, mo months

eFigure 2 FOREST PLOT Exploratory subgroup analyses for Progression free survival (PFS) and Overall survival (OS)



(due to the extreme difference in liposarcoma no hazard ratio for PFS in liposarcoma could be calculated)